Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 SPT Labtech, Semarion Advance Automated Cell-Based Assay Workflows

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

SPT Labtech, Semarion Work to Advance Automated Cell-Based Assay Workflows

The collaboration aims to enable researchers to easily adapt workflows to their applications while improving efficiency and reproducibility.

By: Rachel Klemovitch

Assistant Editor

SPT Labtech, a global leader in innovative laboratory automation, entered a strategic collaboration with Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory, to address unmet drug screening needs. 

The partnership will integrate SPT Labtech’s firefly liquid handling platform with Semarion’s SemaCyte microcarrier technology to develop a flexible, scalable, and automated workflow that simplifies and accelerates key stages of adherent cell assay development.

Together, SPT Labtech and Semarion aim to set a new standard for flexibility and scalability in cell-based assay design, enabling researchers to adapt workflows to their applications while improving efficiency and reproducibility.

The collaboration will overcome long-standing challenges in miniaturizing and automating complex cell biology processes. It will explore the development of joint application protocols, proof-of-concept data, and workflow optimization strategies to provide researchers with more adaptable tools for cell-based discovery.

Jeroen Verheyen, CEO and Co-Founder at Semarion, said: “This partnership demonstrates the impact of combining our innovative microcarrier technology with agile automation. By Integrating our SemaCyte platform with SPT Labtech’s firefly system, we’re unlocking a new class of flexible, miniaturized workflows that streamline assay development and unlock more scalable discovery pipelines.”

Morten Frost, Chief Commercial Officer at SPT Labtech, commented: “This partnership reflects our dedication to innovation that meets researchers where they are—scaling up, scaling down, and adapting as science evolves.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics